Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / NYMX - Nymox Pharmaceutical sees NDA for enlarged prostate drug this summer


NYMX - Nymox Pharmaceutical sees NDA for enlarged prostate drug this summer

Nymox Pharmaceutical (NYMX) plans on filing an NDA for its benign prostatic hyperplasia (BPH) injectable drug fexapotide this summer.The company previously said it would file in Q1 2021.Fexapotide has a new mechanism of action for a BPH drug and works by inducing apoptosis -- cell death -- which selectively removes cells in the enlarged prostate.Fexapotide is also in phase 2 for early-stage prostate cancer.Nymox shares are down 5.5% to $2.27 in morning trading.

For further details see:

Nymox Pharmaceutical sees NDA for enlarged prostate drug this summer
Stock Information

Company Name: Nymox Pharmaceutical Corporation
Stock Symbol: NYMX
Market: NASDAQ
Website: nymox.com

Menu

NYMX NYMX Quote NYMX Short NYMX News NYMX Articles NYMX Message Board
Get NYMX Alerts

News, Short Squeeze, Breakout and More Instantly...